Search
Vincristine
go.drugbank.com/drugs/DB00541ApprovedInvestigationalIt is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. … Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristine sulfate is often chosen as part of polychemotherapy
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: VINRACINE INJ. 1 mg/ml, VINCRISTINA 1 MGTicagrelor
go.drugbank.com/drugs/DB08816ApprovedInvestigational[L14207] Ticagrelor was granted FDA approval on 20 July 2011.[L14201] … [A2903] It is marketed by Astra Zeneca as Brilinta in the US[L14201] and Brilique or Possia in the EU,[L14207]. Ticagrelor was granted EMA approval on 3 December 2010.
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 SubstratesSynonyms: (1S,2S,3R,5S)-3-(7-((1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino)-5-(propylthio)-3H-(1,2,3)triazolo(4,5-d)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diolRifabutin
go.drugbank.com/drugs/DB00615ApprovedInvestigationalA broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients.
Synonyms: 1,4-Dihydro-1-deoxy-1',4-didehydro-5'-(2-methylpropyl)-1-oxorifamycin XIVCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 InducersTeniposide
go.drugbank.com/drugs/DB00444ApprovedInvestigationalTeniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and pr...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 SubstratesProducts: VUMON VM 26 INYECTABLE X 50 MG / 5MLInterferon beta-1b
go.drugbank.com/drugs/DB00068ApprovedInvestigationalProduced in E. coli, no carbohydrates, MW=18.5kD
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme InhibitorsProducts: BETAFERON FOR INJECTION 0.25 mg/mlBenfotiamine
go.drugbank.com/drugs/DB11748ApprovedInvestigationalWithdrawnBenfotiamine has been investigated for the treatment and prevention of Diabetic Nephropathy and Diabetes Mellitus, Type 2.
Products: B-Gamma 150 mg Film Kaplı Tablet (30 adet), Benfodian 150 mg Film Kaplı Tablet (30 adet)Entecavir
go.drugbank.com/drugs/DB00442ApprovedInvestigationalIt is marketed under the trade name Baraclude (BMS). … It was approved by the U.S. Food and Drug Administration (FDA) in March 2005.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesProducts: VORIX® 1.0 MG, OVAMET 1 MG FILM KAPLI TABLET,30 ADETBisacodyl
go.drugbank.com/drugs/DB09020ApprovedInvestigational[A233290,A233300,A207700] Bisacodyl was patented on 25 September 1956[L33045] but has been used as a laxative since 1952.[A233300] … [A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).
Synonyms: Phenol, 4,4'-(2-pyridinylmethylene)bis-, diacetate (ester)Mixtures: BEKUNIS 3 MG/5 MG KAPLI TABLET, 30 ADET, PCP 100 KitCeritinib
go.drugbank.com/drugs/DB09063ApprovedInvestigationalThe FDA approved ceritinib in April 2014 due to a surprisingly high response rate (56%) towards crizotinib-resistant tumours and has designated it with orphan drug status. … This occurrence led to development of novel second-generation ALK inhibitors such as ceritinib to overcome crizotinib resistance.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 InhibitorsSynonyms: N-{2-[(5-chloro-2-{[2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}propane-2-sulfonamidePentazocine
go.drugbank.com/drugs/DB00652ApprovedVet approvedIt is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97)
Products: Pentazocine-Fresenius 30 mg/ml injection, Talwin - Liq 30mg/ml